Increased PARP3 and PARP4 mRNA expression was associated with worsened prognosis in OSCC and PAAD patients, suggesting that inhibition of PARP3/4 could have therapeutic benefit in these patients and highlighting the need for the development of PARP3/4-specific PARPi. Here, PARP3 is linked to pancreatic adenocarcinoma.